Project Grant R43HL176305
Award Date 9/20/25
Completion Date 8/31/26
Dollars Obligated $307K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded Covenant Therapeutics LLC a $249,965 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) on September 10, 2023. The purpose of this grant is to further develop a novel therapeutic approach involving small peptide erythropoietin (EPO) analogs as an alternative to recombinant human EPO for the treatment of anemias, particularly those secondary to renal disease and malignancy. The key objectives are to optimize the lead...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $708,063 in funding to the University of Virginia for a research project titled "Post-Transcriptional Regulatory Networks in Chronic Obstructive Pulmonary Disease". The goal of the 5-year project is to generate RNA-binding protein (RBP) regulatory networks, identify COPD-specific changes, and characterize the functional consequences of the network changes....
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), will support the development of a mathematical model to study the oxygen-dependent equilibrium solubility of sickle hemoglobin in single red blood cells. The $719,128 award has an ultimate completion date of May 31, 2029 and aims to address the unmet need for mechanistic models of...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) provides $730,070 to the University of Arizona to develop and test a novel class of hybrid polyplex nanoparticles (P22-F1 PBAE/PEI/PEG) that can specifically target and deliver DNA plasmids to lung capillary endothelial cells. The goal is to stimulate lung regeneration and decrease pulmonary hypertension in mouse and rat models of bronchopulmonary dysplasia, a severe...
- The federal Project Grant award of $731,827 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is supporting research conducted by the J. David Gladstone Institutes in San Francisco, CA to investigate the mechanisms of oxygen toxicity. The key objectives include: 1) testing whether specific molecular pathways (diphthamide synthesis, de novo purine synthesis, and mitochondrial electron transport chain) are necessary and sufficient for impaired cell...
- This $292,500 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to identify novel microproteins associated with normal hematopoiesis and hematopoietic diseases. The project will leverage existing transcriptomic and translation data to produce a comprehensive catalog of microproteins expressed in different hematopoietic cell types. This inter-disciplinary research conducted by the Sanford Burnham Prebys Medical Discovery...
- This federal Project Grant award, totaling $765,612.15, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research (CFDA 93.837) program. The award supports research to conduct a molecular analysis of airway secretory cells in the context of Chronic Obstructive Pulmonary Disease (COPD), the third leading cause of death in the U.S. and worldwide. The research, taking place at the Research Institute at Nationwide Children's Hospital in Columbus, Ohio,...
- This Project Grant award of $234,000.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Colorado-Denver to develop "hemostatic red blood cells" (T-RBCs) that can bind to collagen and fibrin to enhance clot formation and stability. The goal is to create a novel technology to address severe, non-compressible bleeding, which is a major cause of mortality worldwide, especially in low-resource settings. The...
- The Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $268,500 to Brigham & Women's Hospital Inc. to develop and validate a quantitative marker of pulmonary microvascular injury and explore the correlation between microvascular volume loss and the longitudinal progression of chronic obstructive pulmonary disease (COPD) and emphysema in smokers. The research leverages an AI-based algorithm to assess vascular...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $536,468 to the University of California, San Diego (UC San Diego) to conduct research on protein aggregation in hematopoietic stem cells (HSCs). The project aims to investigate how HSCs, which regenerate blood and immune cells, preferentially traffic misfolded proteins to aggresomes to maintain fitness and self-renewal, and how this process is impacted by...